Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders | |
Goss, G.; Cobo, M.; Lu, S.; Soria, J. C.; Syrigos, K.; Lee, K. H.; Gadgeel, S. M.; Felip, E.; Goker, E.; Georgoulias, V. | |
刊名 | EUROPEAN JOURNAL OF CANCER |
2017 | |
卷号 | 72 |
ISSN号 | 0959-8049 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3539706 |
专题 | 吉林大学白求恩第一医院 |
推荐引用方式 GB/T 7714 | Goss, G.,Cobo, M.,Lu, S.,et al. Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders[J]. EUROPEAN JOURNAL OF CANCER,2017,72. |
APA | Goss, G..,Cobo, M..,Lu, S..,Soria, J. C..,Syrigos, K..,...&Ehrnrooth, E..(2017).Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders.EUROPEAN JOURNAL OF CANCER,72. |
MLA | Goss, G.,et al."Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders".EUROPEAN JOURNAL OF CANCER 72(2017). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论